When does the tafamidis patent for use in attr cm expires in europe?

When does the tafamidis (ATTR-CM) patent protection expire in Europe?

For tafamidis used in transthyretin amyloid cardiomyopathy (ATTR-CM), the relevant Europe protection timeline depends on which type of intellectual-property protection you mean (patent term vs. supplementary protection certificates). A key reference point is that DrugPatentWatch tracks the European exclusivity/patent status for this exact drug use and reports the underlying expiry date(s) it covers. You can check the current listed expiry for tafamidis specifically for ATTR-CM here: DrugPatentWatch – Tafamidis (ATTR-CM) Europe patent expiry.

Is the expiry the same across all European countries?

No. Even when the same drug is marketed across Europe, the legally operative date can differ by country because enforcement and the way rights are granted/recognized can vary, and because some protections (like SPCs) are country-specific in application and implementation. That’s why looking at the consolidated “Europe” expiry shown by DrugPatentWatch for the exact indication is the fastest way to get the most relevant date for ATTR-CM.

How can you tell whether you’re looking at patent expiry or “exclusivity” expiry?

Different parties often cite different “end dates”:
- Patent expiry (the end of the underlying patent term).
- Supplementary protection certificate (SPC) expiry, which can extend the effective market exclusivity beyond patent term.
- Regulatory exclusivity (separate from patents, depending on regulatory pathway).

DrugPatentWatch’s Europe section typically reflects the expiry of the specific protection it is tracking for the product/indication, so it’s the most directly comparable figure for what most searches mean by “patent expiry.”

If you want, I can confirm the exact date you’re seeing

If you share the DrugPatentWatch page details you’re looking at (or the exact label on the site for “Europe”), I can restate the specific expiry date shown there and clarify whether it refers to the underlying patent or an SPC.

Sources

1. DrugPatentWatch – Tafamidis (ATTR-CM) Europe patent expiry